Osteoblasts differentiated from mesenchymal stem cells and composition for treating bone diseases containing the same
A method for differentiating mesenchymal stem cells into osteoblasts using surfactant-coated membranes efficiently addresses the inefficiencies of existing methods, enabling rapid and stable production of osteoblasts for effective bone disease treatment.
Patent Information
- Application Number
- JP2022561156
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-10-08
- Filing Date
- 2021-10-08
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2041-10-08
AI Technical Summary
Existing methods for differentiating mesenchymal stem cells into osteoblasts are inefficient, time-consuming, and unstable, making it difficult to produce them on a large scale for use in cell therapy agents for bone diseases.
A method involving coating an air-permeable polymeric membrane with surfactant bubbles, inoculating mesenchymal stem cells at a specific density, and differentiating them into osteoblasts using a differentiation medium, followed by separation, which allows for rapid and stable production of osteoblasts.
The method enables the stable and rapid differentiation of mesenchymal stem cells into osteoblasts with superior bone reconstruction efficacy, suitable for use as a cell therapy agent for bone diseases.
Smart Images

Figure 0007587866000004 
Figure 0007587866000005 
Figure 0007587866000006
Abstract
Description
[Technical field]
[0001] This application claims priority to Korean Patent Application No. 10-2020-0130138, filed on October 8, 2020, the entire specification of which is incorporated herein by reference. This patent application was filed with the support of the Korea Fund for Regenerative Medicine (KFRM) Grant, funded by the South Korean government (Ministry of Science, ICT and Technology, Ministry of Health and Welfare). [Project ID number] 22D0801L1 [Project Number] 22D0801L1 [Department name] Korean Government (Ministry of Science, ICT and Technology, Ministry of Health and Welfare) [Project Management (specialized) organization name] Korea Foundation for Regenerative Medicine (KFRM) [Research plan name] Korean Government Regenerative Medicine Technology Development Project [Research project name] A phase 1 clinical trial to evaluate the safety and exploratory efficacy of human umbilical cord-derived osteoblast cell therapy CF-M801 in patients with femoral head osteonecrosis [Contribution] 50 / 100 [Project Implementation Organization Name] Sefo Company Limited [Research period] 2022.04.01~2024.12.31 This patent application was filed with the support of the Korea Fund for Regenerative Medicine (KFRM) Grant, funded by the South Korean government (Ministry of Science, ICT and Technology, Ministry of Health and Welfare). [Project ID number] 22C0604L1 [Project Number] 22C0604L1 [Department name] Korean Government (Ministry of Science, ICT and Technology, Ministry of Health and Welfare) [Project Management (specialized) organization name] Korea Foundation for Regenerative Medicine (KFRM) [Research plan name] Korean Government Regenerative Medicine Technology Development Project [Research project name] Development of advanced bioconvergence medical products for the treatment of osteoporotic fractures using umbilical cord-derived osteoblasts [Contribution] 50 / 100 [Project Implementation Organization Name] Sefo Company Limited [Research Period] 2022.04.01~2025.12.31
[0002] The present invention relates to a method for differentiating mesenchymal stem cells into osteoblasts, a cellular therapeutic agent for treating bone diseases containing osteoblasts differentiated by said method, and a method for producing the same.
[0003] The present invention also relates to a method for treating a bone disease, comprising administering the osteoblast obtained by the above method to a patient suffering from the bone disease. [Background technology]
[0004] Stem cells are a collective term for undifferentiated cells that have the pluripotency to differentiate into various cells, and stem cells can differentiate into specific cells depending on specific differentiation factors and / or environments. Types of stem cells include embryonic stem cells, embryonic germ cells, adult stem cells, and cancer stem cells. In recent years, active research has been conducted to treat various diseases, including regeneration of damaged tissues, cartilage damage diseases, diabetes, leukemia, neurological diseases, heart diseases, spinal cord trauma, and fibrotic disorders, using stem cells that can differentiate into various cells, and therefore research is being conducted to differentiate stem cells into specific cells. In addition, induced pluripotent stem cells (iPS), which are created as stem cells through reverse differentiation of differentiated cells, are also used for cell differentiation. In particular, mesenchymal stem cells (MSCs) are multipotent stem cells that have the ability to differentiate into various mesodermal cells, including bone, cartilage, fat, and muscle cells. Due to these capabilities, mesenchymal stem cells are considered valuable as therapeutic agents in the field of regenerative medicine for bone diseases and tissue damage. Regenerative medicine aims to regenerate damaged areas by activating the inherent recovery mechanisms of tissues and organs that were previously unable to recover or by replacing damaged tissues, and includes attempts to culture tissues or organs that the body cannot heal itself in a laboratory and safely transplant or inject them into the body. As a treatment based on regenerative medicine, stem cell therapeutic agents that utilize the self-renewal and differentiation capabilities of stem cells as a treatment method for intractable diseases are attracting attention as next-generation therapeutic agents.
[0005] However, due to risk factors arising from various factors such as the origin of the stem cells used, the site of origin, the degree of culture, the degree of differentiation, etc., the standards for safety and effectiveness are strict, making it difficult to obtain approval. In addition, mass production is required to differentiate stem cells, which have the pluripotency to differentiate into various cells, into specific cells for commercial use, but it is difficult to rapidly and safely differentiate stem cells into bone cells.
[0006] Regarding a method for differentiating stem cells into specific cells, Korean Patent No. 10-2016-0034541 discloses a method for differentiating stem cells into bone cells in a porous membrane coated with hydrogel using sol-gel phase transition, and Korean Patent No. 10-2018-0114307 discloses a method for including hexanoyl glycol chitosan in a medium to promote differentiation of mesenchymal stem cells. US8,580,757B2 discloses a method for using miRNA or siRNA as a method for regulating the differentiation of mesenchymal stem cells. Although various attempts have been made to differentiate mesenchymal stem cells into bone cells, a method for rapidly differentiating a large number of bone cells from stem cells without administering external substances to the stem cells or adding expensive compositions to the differentiation medium has yet to be developed.
[0007] However, further research is still required on methods for stably and rapidly differentiating and culturing osteoblasts from stem cells so that they can be used as cell therapy drugs for bone-related diseases. Summary of the Invention [Problem to be solved by the invention]
[0008] Therefore, the present inventors have invented the present invention while considering an optimal method for producing a bone cell therapeutic agent differentiated from mesenchymal stem cells as one of the regenerative medicine methods for treating bone diseases. The present inventors aim to provide a method for producing osteoblasts for producing a cellular therapeutic agent for treating bone diseases. It has been confirmed that the differentiation method of the present invention allows stable and rapid differentiation into osteoblasts compared to conventional methods for differentiating stem cells for cellular therapeutic agents, and that the osteoblasts have excellent bone reconstruction efficacy, thereby completing the present invention.
[0009] Therefore, an object of the present invention is to provide a method for differentiating mesenchymal stem cells into osteoblasts, a cell therapeutic agent for treating bone diseases containing osteoblasts differentiated by said method, and a method for producing the same. [Means for solving the problem]
[0010] The present invention involves the steps of: i) coating an air-permeable polymeric membrane with a surfactant bubble; ii) Add 1×10 mesenchymal stem cells to the bubble of step i) 3 ~1×10 5 pieces / cm 2 inoculating the oocytes at a density of iii) differentiating the mesenchymal stem cells of step ii) into osteoblasts from a differentiation medium; iv) isolating and obtaining the osteoblasts differentiated in step iii); The present invention provides a method for differentiating mesenchymal stem cells, comprising the step of:
[0011] According to a preferred embodiment of the present invention, the surfactant in step i) may be a poloxamer.
[0012] According to a preferred embodiment of the present invention, the bubbles in step i) may be produced by adding and moving a surfactant on the air-permeable polymer membrane to generate bubbles.
[0013] According to a preferred embodiment of the present invention, the mesenchymal stem cells in step ii) may be derived from any one or more of the group consisting of umbilical cord, umbilical cord blood, placenta, amniotic membrane, bone marrow, fat, hair follicle, tooth, dental pulp, and skin dermis.
[0014] The present invention further provides osteoblasts obtained by the above method.
[0015] According to a preferred embodiment of the present invention, the osteoblasts may have higher expression levels of Connexin 43 (CX43), Runt-related transcription factor 2 (RUNX2) and Collagen type 1A1 (COL1A1) than undifferentiated stem cells and mature bone cells, higher expression levels of Angiopoietin 1 (ANGPT1) and Alkaline Phosphatase (AP) than undifferentiated stem cells, and lower expression levels of Osterix (OSX), Osteocalcin (OCN) and Osteopontin (OPN) than mature bone cells.
[0016] According to a preferred embodiment of the present invention, the osteoblasts may have a lower expression level of Ki-67 compared to undifferentiated stem cells.
[0017] The present invention further provides a cellular therapeutic agent for treating bone diseases, comprising osteoblasts obtained by the above method.
[0018] According to a preferred embodiment of the present invention, the osteoblasts may have higher expression levels of Connexin 43 (CX43), Runt-related transcription factor 2 (RUNX2) and Collagen type 1A1 (COL1A1) than undifferentiated stem cells and mature bone cells, higher expression levels of Angiopoietin 1 (ANGPT1) and Alkaline Phosphatase (AP) than undifferentiated stem cells, and lower expression levels of Osterix (OSX), Osteocalcin (OCN) and Osteopontin (OPN) than mature bone cells.
[0019] According to a preferred embodiment of the present invention, the osteoblasts may have a lower expression level of Ki-67 compared to undifferentiated stem cells.
[0020] According to a preferred embodiment of the present invention, the bone disease may be any one or more selected from the group consisting of fracture, osteonecrosis of the femoral head, spinal fusion, delayed union or nonunion, osteoporosis, osteonecrosis, pseudoarthrosis, Paget's disease and osteogenesis imperfecta.
[0021] The present invention further provides a method for treating a bone disease, comprising administering the osteoblast obtained by the above method to a patient suffering from the bone disease.
[0022] The term "mesenchymal stem cell" as used herein means an adult stem cell that is used in the same sense as a multipotent undifferentiated cell, but has the ability to differentiate into various mesodermal cells, including adipocytes, osteoblasts, chondrocytes, cardiac cells, or muscle cells, or ectodermal cells, such as neural cells. In addition, it is not only free from cancer and ethical issues that are generally problematic with embryonic stem cells, but also may not cause immune rejection after transplantation.
[0023] The term "osteoblast" as used herein refers to a cell that produces bone cells in vertebrates, also known as osteoblasts. They can synthesize and secrete bone matrix to produce bones, and can also become general bone cells by embedding themselves in the bone tissue they have produced. They can also deposit substances necessary for bone, such as Ca and Mg ions, in bones to calcify bone tissue. They can be divided into resting and forming stages depending on the difference in internal substances and activity, and have a high division ability, but their number decreases in old bones.
[0024] In the present invention, the term "bone disease" refers to a condition in which bones are damaged, their structure and density are changed, and bones are prone to fracture. Bones are the hardest tissue in the body, maintaining the stability of the skeletal system, and are used as a lever for muscles, protecting internal organs, and storing minerals such as calcium and magnesium. Such bone diseases are mostly caused by trauma such as fractures, or metabolic diseases such as avascular necrosis and osteoporosis, and regardless of the cause, problems with the mechanical support of the body occur, reducing mobility, and inducing persistent pain due to the formation of tracheal nodes. In the present specification, bone diseases include osteoporosis, osteonecrosis, pseudoarthrosis, Paget's disease, and osteogenesis imperfecta.
[0025] The term "osteoporosis" refers to a condition in which bone mass is reduced and bone strength is weakened due to qualitative changes, making bone fractures more likely. The main causes of osteoporosis are hereditary, early menopause, excessive dietary therapy, steroid drugs, etc.
[0026] The above-mentioned "osteonecrosis" is a disease in which bone tissue dies due to lack of blood supply to the bone. It can occur anywhere in the body, but it mainly occurs in the upper part of the thigh, upper part of the arm, shoulder, knee, and spine.
[0027] The above-mentioned "pseudoarthrosis" is also called "false joint" and refers to a condition in which the broken bone does not join together (non-union) and moves as if it were a joint. It can occur due to a mistake during the healing process after a fracture or due to a bacterial infection at the fracture site.
[0028] The "Paget's disease" is a localized bone disease that occurs mainly in the pelvis, femur, or skull due to excessive bone remodeling, a process in which new bones are generated, grown, and absorbed.
[0029] The above-mentioned "osteogenesis imperfecta" is a general term for a condition in which bones are congenitally weak and easily broken without any particular cause, and is also called bone dysplasia.
[0030] "Differentiation" in the present invention refers to the phenomenon in which structures and functions become specialized while cells divide and grow, i.e., the morphology and function of cells and tissues of an organism change to perform their assigned roles. For example, differentiation refers to the occurrence of qualitative differences between parts of a biological system that were initially homogeneous during ontogeny, or the resulting state in which the system is divided into qualitatively distinct subsystems.
[0031] The "cell therapeutic agent" of the present invention refers to a pharmaceutical product in which cells and tissues isolated, cultured and specially manipulated from an individual are used for therapeutic, diagnostic or preventive purposes, and may be used by a living person through a series of actions such as expanding and selecting allogeneic or xenogeneic cells ex vivo or by otherwise changing the biological properties of cells in order to restore the function of the cells or tissues.
[0032] As mentioned above, conventional cell therapy using stem cells has been difficult to commercialize on a mass scale due to issues such as high unit price, and in particular, there is a drawback in that it takes too much time and money to differentiate stem cells into osteoblasts.
[0033] Meanwhile, the differentiation method according to the present invention can stably and quickly differentiate stem cells at the early stage of subculture into osteoblasts in a short period of time. In conventional stem cell differentiation methods, osteoblasts could not be obtained unless stem cells that had been subcultured 8 times or more were differentiated for more than 20 days, whereas in the present invention, differentiated osteoblasts could be obtained by differentiating stem cells that had been subcultured 5 times for only 3 days (Figure 1). In particular, when using the differentiation method according to the present invention, all stem cells can be differentiated into osteoblasts without any reaction variation due to the donor, and therefore can be used as an allogeneic cell therapy.
[0034] Accordingly, the present invention comprises the steps of: i) coating an air-permeable polymeric membrane with a surfactant bubble; ii) Add 1×10 mesenchymal stem cells to the bubble of step i) 3 ~1×10 5 pieces / cm 2 inoculating the oocytes at a density of iii) differentiating the mesenchymal stem cells of step ii) into osteoblasts from a differentiation medium; iv) isolating and obtaining the osteoblasts differentiated in step iii); The present invention provides a method for differentiating mesenchymal stem cells, comprising the steps of:
[0035] The polymer membrane of step i) may be the porous membrane of a Hyperflask.
[0036] The density of step ii) is preferably 1×10 3 ~1×10 5 pieces / cm 2 More preferably, 1×10 4 pieces / cm 2 may be also possible.
[0037] According to a preferred embodiment of the present invention, the surfactant in step i) may be a poloxamer. Surfactants other than poloxamer are cytotoxic (Example 4) and are not suitable for the present invention. The poloxamer may be any one or more selected from the group consisting of poloxamer 184, poloxamer 185, poloxamer 188, poloxamer 124, poloxamer 237, poloxamer 338 and poloxamer 407.
[0038] The surfactant in step i) may be up to 10% surfactant.
[0039] The bubbles in step i) may be generated by moving a surfactant on the air-permeable polymer membrane. For example, the bubbles in step i) may be generated by shaking a surfactant on the air-permeable polymer membrane or by pipetting, but are not limited thereto.
[0040] According to a preferred embodiment of the present invention, the mesenchymal stem cells in step ii) may be derived from any one or more selected from the group consisting of umbilical cord, umbilical cord blood, placenta, amniotic membrane, bone marrow, fat, hair follicle, tooth, dental pulp, and skin dermis. More preferably, the mesenchymal stem cells in step ii) may be umbilical cord-derived mesenchymal stem cells.
[0041] The umbilical cord-derived mesenchymal stem cells have the advantage that they can be easily collected and a large amount of stem cells can be easily secured by using umbilical cord tissue discarded after childbirth. Stem cells derived from fat or bone marrow have limited proliferation and differentiation abilities and are highly variable depending on the age and health condition of the donor from which they are isolated and extracted, but umbilical cord-derived stem cells are the stem cells that can be obtained at the earliest stage among adult stem cells, and are hardly affected by variables such as the age of the donor, and have excellent proliferation and differentiation abilities. In addition, umbilical cord-derived mesenchymal stem cells have the advantage that stem cell groups that can be used for various diseases such as nervous system diseases, liver diseases, and musculoskeletal diseases can be isolated.
[0042] In step ii), the mesenchymal stem cells may be seeded into the bubbles when the bubbles begin to disappear at least 2 hours after coating the air-permeable polymer membrane with the surfactant bubbles.
[0043] The mesenchymal stem cells in step ii) may be stem cells that have been cultured for 5 to 8 passages, and more preferably, may be stem cells that have been cultured for 5 to 6 passages.
[0044] The mesenchymal stem cells inoculated in step ii) may be cultured in a culture medium that may contain at least one selected from the group consisting of α-MEM, DMEM, and FBS for 12 to 48 hours before being differentiated into osteoblasts from a differentiation medium, and more preferably, may be cultured in the culture medium for 20 to 30 hours.
[0045] The differentiation in step iii) may be carried out for 24 hours to 120 hours, and more preferably for 60 hours to 80 hours.
[0046] According to a preferred embodiment of the present invention, the osteoblasts may have higher expression levels of Connexin 43 (CX43), Runt-related transcription factor 2 (RUNX2) and Collagen type 1A1 (COL1A1) than undifferentiated stem cells and mature bone cells, higher expression levels of Angiopoietin 1 (ANGPT1) and Alkaline Phosphatase (AP) than undifferentiated stem cells, and lower expression levels of Osterix (OSX), Osteocalcin (OCN) and Osteopontin (OPN) than mature bone cells.
[0047] According to a preferred embodiment of the present invention, the osteoblasts may have a lower expression level of Ki-67 compared to undifferentiated stem cells.
[0048] The osteoblasts of the present invention have significantly higher expression of Connexin 43 (CX43), Runt-related transcription factor 2 (RUNX2), collagen type 1A1 (COL1A1), and alkaline phosphatase (AP), which are expressed in early osteoblasts, than undifferentiated stem cells, and the expression of Ki-67, a cell proliferation marker, is decreased compared to undifferentiated cells, but is still expressed, indicating that they are early osteoblasts in which cell proliferation occurs by forming colonies. In contrast, the expression levels of Osterix (OSX), Osteocalcin (OCN), and Osteopontin (OPN), which increase in expression as the osteocyte becomes fully mature, were lower than those of mature osteocytes (NHOst). In addition, the expression of angiopoietin 1 (ANGPT1), which is clearly expressed in early osteoblasts, also increased several hundred-fold in both gene and protein expression, clearly demonstrating the characteristics of early osteoblasts (Table 1).
[0049] [Table 1]
[0050] Said CX43 is encoded by GJA1 gene and is the most common gap junction protein expressed in bone cell types such as chondrocytes, osteoblasts, osteoclasts, etc. CX43 plays an important role in regulating signal transmission between various bone cell types and regulates bone development, differentiation, modeling and remodeling as well as pathology. In particular, CX43 is necessary for the survival, proliferation and differentiation of osteoblasts and can enhance the expression of various bone formation markers.
[0051] RUNX2 is a key regulator of osteocyte differentiation and an important transcription factor that regulates the expression of alkaline phosphatase (ALP), an early phenotype of osteoblast differentiation, and osteocalcin (OCN), a late phenotype. Immature osteoblasts are RUNX2+, have proliferation capacity, and differentiate into mature bone cells, which then undergo mineralization. Osteoblasts continue to divide for a certain period of time, and as they differentiate, they gradually lose their division capacity and differentiate into bone cells (Figures 17a and 17b).
[0052] The collagen type 1A (COL1A1) is an osteogenic marker that is characteristically expressed during differentiation into osteoblasts.
[0053] Osterix (OSX) is a differentiation factor associated with bone cell formation. OSX plays an important role in differentiating osteoblasts into mature osteoblasts by increasing the expression of bone matrix protein through enhancing COL1A1 promoter activity.
[0054] The osteocalcin (OCN) corresponds to a differentiation factor related to bone cell formation. OCN is formed in osteoblasts and then deposited in the bone matrix. Some of the newly formed OCN is then released into the blood, so the level of bone formation can be determined by measuring the blood concentration.
[0055] The osteopontin (OPN) is a differentiation factor associated with bone cell formation and corresponds to an osteogenic marker protein.
[0056] The present invention can further provide a cellular therapeutic agent for treating bone diseases, comprising osteoblasts obtained by the above method.
[0057] According to a preferred embodiment of the present invention, the osteoblasts may have higher expression levels of Connexin 43 (CX43), Runt-related transcription factor 2 (RUNX2) and Collagen type 1A1 (COL1A1) than undifferentiated stem cells and mature bone cells, higher expression levels of Angiopoietin 1 (ANGPT1) and Alkaline Phosphatase (AP) than undifferentiated stem cells, and lower expression levels of Osterix (OSX), Osteocalcin (OCN) and Osteopontin (OPN) than mature bone cells.
[0058] According to a preferred embodiment of the present invention, the osteoblasts may have a lower expression level of Ki-67 compared to undifferentiated stem cells.
[0059] According to a preferred embodiment of the present invention, the bone disease may be any one or more selected from the group consisting of fracture, osteonecrosis of the femoral head, spinal fusion, delayed union or nonunion, osteoporosis, osteonecrosis, pseudoarthrosis, Paget's disease and osteogenesis imperfecta.
[0060] The present invention may further provide a method for treating a bone disease, comprising administering the osteoblast obtained by the above method to a patient suffering from a bone disease.
[0061] The administration may be parenteral and the osteoblasts may be administered alone or in combination with procedures using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers. Effect of the Invention
[0062] The differentiation method according to the present invention can stably and rapidly differentiate mesenchymal stem cells into osteoblasts. The differentiated osteoblasts have excellent angiogenic and osteogenic abilities. Therefore, the method of differentiating stem cells into osteoblasts according to the present invention and the osteoblasts obtained by the method can be effectively used as a cell therapy for bone diseases. [Brief description of the drawings]
[0063] [Figure 1] FIG. 1 shows the process for differentiating and obtaining umbilical cord-derived osteoblasts of the present invention. [Diagram 2] Figure 2 shows the results of observing whether the poloxamer bubbles remaining on the porous membrane were retained for 7 hours (0H~7H) after removing the poloxamer solution after poloxamer bubble coating. It was confirmed that the bubbles disappeared 2 hours (2H) after removing the poloxamer solution. [Diagram 3] Figure 3 shows 3D fluorescence microscopy images of poloxamer bubble coating followed by loading of QD-treated cells. [Figure 4] Figure 4 shows the results of a cytotoxicity experiment for each type of surfactant. It was confirmed that the surfactants (DIAPON K-SF and Tween-20) other than P407 (poloxamer 407), which is the result of CCK-8 (cell counting kit-8) on the first day, were toxic to cells. [Diagram 5] Figure 5 shows the results of a cytotoxicity experiment for each type of surfactant. As a result of checking cell proliferation using CCK-8 (cell counting kit-8) from 1 to 3 days, it was confirmed that the remaining surfactants (DIAPON K-SF and Tween-20) except for P407 (poloxamer 407) were cytotoxic and did not cause cell proliferation. [Figure 6]Figure 6 shows the results of a cytotoxicity experiment for each type of surfactant. It was confirmed that the remaining surfactants (Methylprednisolone and Tween-20) except for P407 (Poloxamer 407) showed toxicity to cells, as shown in the results of CCK-8 (cell counting kit-8) on the first day. [Figure 7] Figure 7 shows the results of a cytotoxicity experiment for each type of surfactant. As a result of checking cell proliferation using CCK-8 (cell counting kit-8) from 1 to 3 days, it was confirmed that the remaining surfactants (Methylprednisolone and Tween-20) except for P407 (Poloxamer 407) were cytotoxic and did not cause cell proliferation. [Figure 8] FIG. 8 shows that the expression level of a gene (COL1A) was significantly higher in cells differentiated from bubble foam surfactant than in undifferentiated cells or cells differentiated from gel surfactant. [Figure 9] FIG. 9 shows that the expression level of a protein (VEGF) was significantly higher in cells differentiated from bubble foam surfactant than in undifferentiated cells or cells differentiated from gel surfactant. [Figure 10] Figure 10 shows the results of comparing the expression levels of bone induction genes in differentiated cell therapeutic agents of the present invention (RCB001-DP1 to RCB005-DP5) to undifferentiated cells (RCB001, RCB002, RCB005). It was confirmed that the expression levels of Connexin 43 (CX43) and Runt-related transcription factor 2 (RUNX2) secreted from the cell therapeutic agents of the present invention were significantly increased in undifferentiated cells. [Figure 11]11 shows the results of comparing the expression levels of osteoinductive genes of the differentiated cell therapy of the present invention (RCB005-DP1) with undifferentiated cells (RCB005), bone marrow-derived mesenchymal stem cells (BM-MSCs) and mature osteoblasts (NHOst). The expression levels of early osteoblast markers Connexin 43 (CX43), Runt-related transcription factor 2 (RUNX2) and Collagen type 1A1 (COL1A1) were higher than those of undifferentiated cells and mature osteoblasts, and the expression levels of Osterix (OSX), Osteocalcin (OCN) and Osteopontin (OPN) were lower than those of mature osteoblasts (NHOst). [Figure 12] 12 shows that the osteogenic marker protein and the angiogenic marker protein were increased in the differentiated bone cell therapeutic agent of the present invention compared to undifferentiated cells. (A) represents COL1A1, (B) represents osteopontin (OPN), and (C) represents angiopoietin. [Figure 13] 13 shows that the differentiated cell therapeutic agent of the present invention maintains bone formation marker proteins and angiogenesis marker proteins even 3 to 7 days after thawing. (A) represents COL1A1, (B) represents osteopontin (OPN), and (C) represents angiopoietin. [Figure 14] 14 shows the vascular endothelial vessel formation ability of the umbilical cord-derived osteoblasts of the present invention. It was confirmed that angiogenesis was induced by the umbilical cord-derived raw cell (Undifferentiated UCMSC) and osteogenic differentiation cell therapeutic agent to the same extent as the VEGF positive control group, which is known as an angiogenesis-inducing factor, and in particular, it was confirmed that the blood vessels formed by the proteins secreted by the cell therapeutic agent were thicker and stronger. [Figure 15]Figures 15a and 15b show the results of efficacy of the cell therapeutic agent of the present invention in large animals (goats). [Figure 16] FIG. 16 shows the results of efficacy of the cell therapeutic agent of the present invention in small animals (rats). [Figure 17] 17a and 17b show the differentiation stages of mesenchymal stem cells into bone cells. The area indicated by the dotted line represents the stage of the cell therapy agent of the present invention. [Figure 18] Figure 18 shows the results of confirming the cell division ability of two batches of undifferentiated UCMSCs (raw material) and differentiated osteoblasts (DP) using Ki-67 (an indicator of cell division). It was confirmed that Ki-67 expression was consistently and rapidly decreased to less than 1% from DP, which means that CF-M801 is an early stage osteoblast of the osteoblast model. [Figure 19] Figures 19a and 19b show the results of measuring CFU-F using two batches of undifferentiated stem cells BMMSC and UCMSC (raw material) and differentiated osteoblasts (DP). It was confirmed that the differentiated osteoblasts (DP, CF-M801) showed a decrease in CFU-F in a pattern similar to that of Ki-67 (an indicator of cell division) expression. [Figure 20] Figure 20 shows the results of measuring absorbance after staining with alkaline phosphatase after colonies were formed using two batches of undifferentiated stem cells UCMSC (raw material) and differentiated osteoblasts (DP). Colonies formed by differentiated osteoblasts (DP) were stained with alkaline phosphatase compared to undifferentiated cells, and the absorbance value increased, confirming that the colonies formed by proliferation of this cell therapy were osteoblasts. [Figure 21] 21a and 21b show that the differentiated osteoblasts (DP1 to DP3) of the present invention express CD10 at 80% or more, whereas undifferentiated mesenchymal stem cells express CD10 at 15% or less. This means that the osteoblasts of the present invention are controlled by confirming the purity by confirming osteoblast-specific marker factors that are not conventional stem cell marker factors. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0064] [Example 1] Isolation and harvesting of umbilical cord-derived stem cells First, the arteries and veins were removed from the isolated umbilical cord, and the remaining tissue was finely minced and then soaked in AdiCol. TM After incubation with CEFO at 37°C for 30 minutes or more, the cells were extracted. TM Incubate in culture at 37°C, 5% CO 2 The cells were cultured under these conditions to obtain mesenchymal stem cells.
[0065] [Example 2] Coating an air-permeable polymer membrane with surfactant bubbles After shaking 8% poloxamer 407 completely dissolved in PBS on the porous membrane of a Hyperflask to generate bubbles, the remaining poloxamer solution was poured in. The air-permeable polymer membrane was coated with the poloxamer bubbles at 37°C for 2 hours. After the poloxamer 407 bubbles were generated, the solution was removed to observe whether the bubbles were maintained using microscopic 3D imaging. It was confirmed that the bubbles began to disappear after 2 hours (2H) and had completely disappeared after 5 hours (5H) (Figure 2).
[0066] In addition, to enable tracking of umbilical cord-derived mesenchymal stem cells, quantum dot-conjugated silica nanoparticles (QDs) were uptaken into stem cells for 24 hours. After poloxamer 407 bubbles were generated, the solution was removed, and cells were loaded and imaged in 3D using a Z-stack microscope (Figure 3).
[0067] [Example 3] Differentiation and culture of osteoblasts Two hours after coating with poloxamer bubbles in [Example 2], 1×10 4 pieces / cm 2 The cells were seeded at 100% density and cultured for 24 hours in a culture medium containing DMEM and FBS. The cultured stem cells were differentiated into osteoblasts in a bone differentiation medium for 72 hours.
[0068] [Example 4] Screening of surfactants suitable for coating air-permeable polymeric membranes The toxicity of poloxamer 407 (P407), sodium methyl cocoyl taurate (DIAPON K-SF), polyethylene sorbitan monolaurate (Tween 20), and methylprednisolone, which are known to be representative biocompatible surfactants, was examined.
[0069] Specifically, the upper chamber of a transwell containing a three-dimensional porous membrane was treated with surfactant P407, DIAPON K-SF, or Tween 20 at 0, 0.51, 5, or 15% (v / v), respectively, and coated for 2 hours in the same manner as in [Example 2] above, and then the umbilical cord-derived mesenchymal stem cells obtained in [Example 1] above were added at 20,000 cells / cm. 2 The lower chamber was filled with cell growth medium and cultured for 3 days. On the 1st, 2nd, and 3rd days, CCK-8 (Cat. CK04, DOJINDO) solution was added and incubated at 37°C and CO 2 After incubation in an incubator for 3 hours, the absorbance was measured at 450 nm to analyze the cytotoxicity (FIG. 4) and cell proliferation (FIG. 5).
[0070] In addition, the upper chamber of a transwell containing a three-dimensional porous membrane was treated with surfactant P407, methylprednisolone or Tween 20 at a concentration of 4 mM and coated for 2 hours in the same manner as in [Example 2] above, and then the umbilical cord-derived mesenchymal stem cells obtained in [Example 1] above were added at a density of 20,000 cells / cm. 2 The lower chamber was filled with cell growth medium and cultured for 3 days. On days 1, 2, and 3, CCK-8 solution was added and the cells were incubated at 37°C and CO 2After incubation in an incubator for 3 hours, the absorbance was measured at 450 nm to analyze the cytotoxicity (FIG. 6) and cell proliferation (FIG. 7).
[0071] As a result, as shown in [Figures 4] to [Figures 7], it was confirmed that, except for P407, DIAPON K-SF, Tween 20, and methylprednisolone all exhibited toxicity to cells.
[0072] [Example 5] Selection of surfactant coating methods Poloxamer was coated on the Hyperflask porous membrane in bubble or gel form, and the degree of osteogenic differentiation of umbilical cord-derived stem cells differentiated according to the method of [Example 3] was compared.
[0073] Specifically, the differentiated osteoblasts and undifferentiated cells were collected and incubated with Trizol. TM The mixture was treated with chloroform (Sigma) and centrifuged to separate the layers, obtaining only mRNA. The obtained mRNA was synthesized as cDNA using the Transcriptor Universal cDNA Master Kit (Roche). Then, DNA was amplified by RT-PCR for COL1A1 to confirm the difference in DNA copy number at the gene level. The polymerase chain reaction conditions were 95°C for 10 seconds, 54°C for 10 seconds, and 72°C for 30 seconds, for a total of 50 cycles (Figure 8).
[0074] In addition, the culture medium of the osteoblasts and undifferentiated cells prepared and induced to differentiate by the method of [Example 3] was collected, and the secretion level of vascular endothelial growth factor (VEGF) was measured by enzyme-linked immunosorbent assay (ELISA) (Figure 9).
[0075] As a result, as shown in [Figures 8] and [Figure 9], it was confirmed that the expression levels of bone inductive genes and angiogenic inductive proteins in cells differentiated by the method of the present invention were significantly superior to those of undifferentiated cells or cells differentiated from gel-like poloxamer.
[0076] [Example 6] Evaluation of bone formation ability of the obtained osteoblasts <6-1> Bone formation ability of osteoblasts (gene level) RNA was isolated from osteoblasts collected during osteoblast differentiation, cDNA was synthesized, and gene expression levels of bone formation gene markers Runt-related transcription factor 2 (RUNX2) and Connexin 43 (CX43) were compared with those of undifferentiated cells using real-time polymerase chain reaction (RT-PCR).
[0077] Specifically, osteoblasts and undifferentiated cells produced and induced to differentiate by the method of Example 3 were collected, and then incubated with Trizol. TM The mixture was treated with chloroform (Sigma) and centrifuged to separate the layers, obtaining only mRNA. The obtained mRNA was synthesized as cDNA using the Transcriptor Universal cDNA Master Kit (Roche). Then, DNA was amplified through RT-PCR for RUNX2 and CX43 to confirm the difference in expression level at the gene level. The polymerase chain reaction conditions were 95℃ 10 seconds, 54℃ 10 seconds, and 72℃ 30 seconds, for 50 cycles.
[0078] In addition, osteoblasts, undifferentiated cells, bone marrow-derived mesenchymal stem cells (BM-MSCs), and mature osteocytes (NHOst) produced and induced to differentiate by the method of [Example 3] were collected to obtain mRNA, and the obtained mRNA was synthesized with cDNA using Transcriptor Universal cDNA Master Kit (Roche). Then, DNA was amplified by RT-PCR for RUNX2, CX43, and COL1A to confirm the expression level difference at the gene level. The polymerase chain reaction conditions were 95°C for 10 seconds, 54°C for 10 seconds, and 72°C for 30 seconds, for 50 cycles.
[0079] As a result, as shown in Figures 10 and 11, it was confirmed that RUNX2, CX43, or COL1A is highly expressed in the osteoblasts of the present invention relative to undifferentiated stem cells and mature bone cells (NHOst). In Figure 10, RCB001, RCB002, and RCB005 represent undifferentiated cells, and RCB001-DP1 to RCB005-DP5 represent differentiated cell therapeutic agents of the present invention.
[0080] On the other hand, in the case of OSX, OCN, and OPN, they were expressed more highly in mature bone cells (NHOst) than in the osteoblasts of the present invention, indicating that the osteoblasts of the present invention are at an immature bone differentiation stage compared to NHOst (Figure 11). In Figure 11, RCB001, RCB002, and RCB005 represent undifferentiated cells, and RCB001-DP1 to RCB005-DP5 represent differentiated cell therapeutic agents of the present invention.
[0081] <6-2> Bone formation ability of osteoblasts (protein level) The changes in protein concentrations of collagen type 1A (COL1A), osteopontin, and angiopoietin (ANGPT-1), which are known as bone formation or angiogenesis protein markers, were confirmed in the culture medium and osteoblasts collected during the osteoblast differentiation process in [Example 3]. Furthermore, it was confirmed whether the frozen cell therapy agent of the present invention could maintain bone formation proteins or angiogenesis proteins even after thawing.
[0082] Specifically, osteoblasts prepared and induced to differentiate by the method of [Example 3], undifferentiated cells, and differentiation culture medium were collected and subjected to enzyme-linked inmunosorbent assay (ELISA). For COL1A, differentiation-induced cells and undifferentiated cells were collected, and the degree of change in intracellular protein expression was confirmed by lysing the cells, while for osteopontin and angiopoietin, the degree of protein secretion was confirmed in the culture medium up to 72 hours after differentiation.
[0083] As a result, as shown in FIG. 12, it was confirmed that the expression of COL1A protein increased in the osteoblasts of the present invention, and that the secretion of osteopontin and angiopoietin was all highly expressed. In addition, as shown in FIG. 13, it was confirmed that the bone morphogenetic protein or blood vessel induction protein of the cell therapy agent of the present invention was maintained even after 3 to 7 days after thawing. In FIG. 12 and FIG. 13, (A) represents COL1A1, (B) represents osteopontin (OPN), and (C) represents angiopoietin.
[0084] [Example 7] Evaluation of angiogenic potential of the obtained osteoblasts The angiogenic potential of human umbilical vein endothelial cells (HUVECs) was confirmed by the angiogenic proteins secreted by the osteoblasts obtained.
[0085] Specifically, 4 × 10 undifferentiated stem cells or osteoblasts were cultured on a 12-well transwell plate containing a porous membrane with a pore size of 8.0 μm. 4 After seeding at 1000 cells / well and allowing the quantum dots to be uptaken for 24 hours using cultured HUVEC cells, the cells were harvested and placed under the transwell at 25,000 / cm 2 The cells were seeded at a density of 1000 x 1000 mm. After seeding, they were co-cultured for 1 day and an experiment to analyze the vascular tube formation of HUVEC was performed. Each cell was seeded into a 12-well plate, and after medium and material exchange was performed using a transwell, the cells were cultured for 12 hours to confirm the vascular induction of HUVEC cells. Osteoblast-differentiated cells and undifferentiated cells were placed on the transwell for comparison. The negative control group was seeded with only HUVEC cells on a coated Matrigel plate and cultured for 12 hours in HUVEC medium without VEGF, and the positive control group was cultured under the same conditions as the negative control group, with the addition of VEGF 20 ng / ml.
[0086] As a result, as shown in Figure 14, it was confirmed that tube formation occurred when umbilical cord-derived raw material cells (Undifferentiated UC-MSC) were co-cultured with a bone cell therapeutic agent at a level similar to that of the positive control group, which showed VEGF, known as an angiogenesis-inducing factor. In addition, it was confirmed that thick and strong blood vessels were formed when co-cultured with osteogenic differentiation cell therapeutic agent, and in particular, it was confirmed that the blood vessels formed by the proteins secreted by the cell therapeutic agent were thicker and stronger.
[0087] [Example 8] Confirmation of bone regeneration ability of the obtained osteoblasts - in vivo After inducing bone defects in large animal (goat) or small animal (rat) models, the bone regenerative ability of the cell therapy agent of the present invention was confirmed.
[0088] Specifically, after inducing femoral defects in an immunosuppressed goat model, 1 × 107 The bone regeneration effect was confirmed after 26 weeks of osteoblast treatment (Table 2). In addition, as an efficacy test for a goat model, the bone tissue was decalcified for 2.5 months, and the efficacy of this cell therapy was evaluated histologically using H&E and Masson's Trichrome staining.
[0089] In the case of an immunosuppressed rat model, after induction of radial bone defect, 1 × 10 6 The bone regeneration effect was confirmed after 12 weeks of osteoblast treatment (Table 3). The sham control group was treated with only the alginate scaffold. The degree of bone regeneration was confirmed by μCT imaging, and the bone tissue was fixed, decalcified, sectioned, and slides were prepared, and new bone regeneration was confirmed after staining.
[0090] [Table 2]
[0091] [Table 3]
[0092] As a result of efficacy testing on a goat model, as shown in Figures 15a and 15b, at 26 weeks, new bone formation was very insufficient and only partially observed in the proximal and distal parts of the control group in both males and females, and it was confirmed that the wound was in the process of healing. On the other hand, in the proximal and distal parts of the cell-administered group, cells were packed into the defect site, proliferated and differentiated into bone cells, and the new bone columns were organically well connected without interruption and were considerably thicker (white arrow in the lower left of Figure 15a). Blood vessels were also found to be well formed in an orderly manner. It was confirmed that new bone formation was significantly observed only in the cell-administered group at both 13 and 26 weeks.
[0093] As a result of the efficacy test on the rat model, as shown in Figure 16, the G3 group was the cell therapy group differentiated for 2 days at passage 7, and the G5 group was the therapy group differentiated for 3 days at passage 5. Both groups showed a tendency to increase bone volume, bone volume density, BMD, etc. compared to the control group, but it was confirmed that the bone volume of the therapy group differentiated for 3 days at passage 5 was more significantly increased.
[0094] [Example 9] Confirmation of cell therapy stage The steps of the cell therapy agent of the present invention were confirmed.
[0095] <9-1> Confirmation of Ki-67 expression It is known that human Ki-67 is not expressed during the resting phase (G0) of the cell cycle, but is expressed during the proliferation phase (G1, S, G2, M phases), and the cell therapy agent is not expressed after differentiation into osteocytes because the cells do not proliferate. Therefore, the cell division ability of two batches of undifferentiated UCSMC (raw material) and differentiated osteoblasts (DP) of the present invention was confirmed by immunofluorescence (ICC) for the expression level of Ki-67, an indicator of cell division, and the expression level of Ki-67 was corrected for the number of cells by staining with DAPI, a nuclear staining substance.
[0096] Specifically, prepare a slide plate and place 3 × 10 5 After inoculating the undifferentiated and differentiated cells in 10 mL of 10 ... 2 The cells were cultured in an incubator. The cells were fixed with 4% formaldehyde for 10 minutes at room temperature, and permeabilized with 1% Triton X-100 for 10 minutes at room temperature. After blocking with BSA for 30 minutes at room temperature, the cells were incubated with Ki-671 primary antibody for 1 hour at room temperature, and with fluorescently linked secondary antibody for 1 hour at room temperature in the dark. TM The cells were mounted using Gold Antifade Mountant (Invitrogen) and observed under a fluorescent microscope.
[0097] As a result, as shown in FIG. 18, it was confirmed that Ki-67 expression consistently decreased sharply to less than 1% in osteoblasts (DP).
[0098] <9-2> Confirmation of CFU-F expression CFU-F was measured using two batches of undifferentiated stem cells BMMSC, UCMSC (raw material) and differentiated osteoblasts (DP) of the present invention. It is also known that mesenchymal stem cells begin to grow and form characteristic cell colonies when in vitro culture is started, and the cells in the colonies show a fibroblast-like shape, and each cell colony is called a colony forming unit-fibroblast, which is known to be an important characteristic of stem cells. Therefore, the formed colonies were stained with 2% crystal violet, and then observed visually and photographed, and the stained colonies were quantified by counting those that were 3 mm or larger and had a density of 80% or more.
[0099] As a result, as shown in Figures 19a and 19b, it was confirmed that differentiated osteoblasts (DP, CF-M801) showed a decrease in CFU-F in a pattern similar to the expression of Ki-67 (an indicator of cell division). It was also confirmed that while a large number of colonies were formed using the source cells, which were bone marrow-derived stem cells and umbilical cord-derived stem cells, the cell therapy agent was unable to form any colonies. This led to the conclusion that the umbilical cord-derived stem cell source cells had lost their ability to form colonies by differentiating into osteogenic cells. This result confirmed that the cell therapy agent had differentiated most of the source cells.
[0100] <9-3> Confirmation of ALP expression We confirmed whether the colony-forming cells that appeared at an average of less than 1% in CFU-F using the cell therapy agent CF-M801 were undifferentiated mesenchymal stem cells or cells induced to differentiate into bone (osteoblasts).
[0101] Specifically, colonies that appeared after culturing in the same manner as CFU-F in Example <9-2> were stained with ALP (Alkaline Phosphatase) staining to confirm the presence or absence of osteogenic differentiation. 10,000 cells were inoculated and maintained for 1 week, after which ALP staining was performed. After ALP staining, dimethylsulfoxide was reacted to fully dissolve the stain, and only the supernatant was collected, and the absorbance was measured using a microplate reader.
[0102] As a result, as shown in [Figure 20], undifferentiated UCMSC, which is an allogeneic umbilical cord-derived mesenchymal stem cell, showed almost no ALP staining, but it was confirmed that all colonies of CF-M801 induced to differentiate into bone were ALP positive in three different lots. In addition, CF-M801 induced to differentiate into bone showed higher absorbance than undifferentiated cells. When this was converted into a relative value and analyzed, it was found to be 1.5 times higher than undifferentiated UCMSC in all cases. As a result, it was confirmed that differentiated osteoblasts (DP) are in a state where cell division does not stop for a certain period of time, and as differentiation progresses, they gradually lose their ability to divide and differentiate into bone cells.
[0103] Overall, the cell therapy of the present invention can differentiate mesenchymal stem cells into osteoblasts by RUNX2, a master regulator of osteocyte differentiation. It was found that early stage osteoblasts (osteo-progeniotrs, immature osteoblasts) are RUNX2+, have proliferation ability, differentiate into mature osteocytes, and further undergo mineralization (Figures 17a and 17b).
[0104] <9-4> Confirmation of CD-10 expression To confirm the differentiation of cell therapy agents, the expression level of CD10 was confirmed by flow cytometry (FACS) and immunocytochemistry (ICC).
[0105] Specifically, osteoblasts, undifferentiated cells, and bone marrow-derived mesenchymal stem cells (BM-MSCs) prepared and induced to differentiate by the method of [Example 3] were suspended in 2% BSA / DPBS solution. The cells were reacted with CD10 primary antibody for 1 hour at room temperature, washed, and then reacted with FITC fluorescent-linked secondary antibody for 30 minutes at room temperature. After washing the cells, the supernatant was removed, and the cells were fixed with 3.7% formaldehyde for 20 minutes at room temperature, and the expression level of CD10 was confirmed using flow cytometry (BD Accuri C6 Plus).
[0106] The ICC prepared slide plates and placed 3 × 10 5 After inoculating the undifferentiated and differentiated cells in 10 mL of 10 ... 2 The cells were cultured in an incubator. The cells were fixed with 4% formaldehyde for 10 minutes at room temperature, and permeabilized with 1% Triton X-100 for 10 minutes at room temperature. After blocking with BSA for 30 minutes at room temperature, the cells were incubated with CD101 primary antibody for 1 hour at room temperature, and with FITC fluorescent-linked secondary antibody for 1 hour at room temperature in the dark. TM The cells were mounted using Gold Antifade Mountant (Invitrogen) and observed under a fluorescent microscope.
[0107] As a result, as shown in [Figure 21a] and [Figure 21b], it was confirmed that the differentiated osteoblasts (DP1 to DP3) of the present invention expressed CD10 at 80% or more, whereas the undifferentiated mesenchymal stem cells expressed CD10 at 15% or less. This meant that the osteoblasts of the present invention were confirmed to have osteoblast-specific marker factors that were not conventional stem cell marker factors, and their purity was confirmed and controlled. [Industrial Applicability]
[0108] The differentiation method according to the present invention can stably and rapidly differentiate mesenchymal stem cells into osteoblasts. The differentiated osteoblasts have excellent angiogenic and osteogenic abilities. Therefore, the method of differentiating stem cells into osteoblasts according to the present invention and the osteoblasts obtained by the method can be effectively used as a cell therapy agent or a treatment method for bone diseases, and have industrial applicability.
Claims
1. i) coating an air-permeable polymeric membrane with poloxamer bubbles; ii) Add 1×10 mesenchymal stem cells to the bubble of step i) 3 ~1×10 5 pieces / cm 2 and inoculating the oocytes at a density of iii) differentiating the mesenchymal stem cells of step ii) into osteoblasts in a differentiation medium; iv) isolating and obtaining the osteoblasts differentiated in step iii); Including, The bubbles of step i) are prepared by moving a poloxamer over the air-permeable polymeric membrane to generate bubbles. A method for differentiating mesenchymal stem cells into osteoblasts.
2. The method of claim 1, wherein the mesenchymal stem cells in step ii) are derived from any one or more selected from the group consisting of umbilical cord, umbilical cord blood, placenta, amniotic membrane, bone marrow, fat, hair follicle, tooth, dental pulp, and skin dermis.
Citation Information
Patent Citations
Isolation and culture method of umbilical cord mesenchymal stem cells
CN110577929A
Preventing and treating agent of bone disorder accompanied by bone fracture and reduction of bone mass
JP2008297220A
Bone differentiation inducing agent
JP2009256350A
Cell Therapy for bone regeneration and method of manufacturing the same
KR1020180087870A
Use of poloxaminesines as inducers of the osteogenic differentiation of mesenchymal cells
US20130156724A1
